Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
ipo
7
×
national blog main
national top stories
vc
7
×
biotech
boston blog main
life sciences
new york blog main
san diego blog main
san diego top stories
san francisco blog main
venture capital
boston top stories
new york top stories
san francisco top stories
texas blog main
texas top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
startups
wisconsin blog main
wisconsin top stories
biogen
cancer
celgene
deals
drug development
fda
funding
gene editing
gene therapy
What
bio
roundup
ipo
new
company
medicines
activity
advance
agtech
aiming
allogene
ambys
approvals
based
becker
big
billions
biogen
biology
biopharma
biotech
blockchain
cancer
car
caught
celgene
chargify
clamped
colleagues
control
covid
crispr
cytokine
deadly
deal
debuted
delays
developing
diseases
diversity
Language
unset
Current search:
ipo
×
vc
×
@xconomy.com
3 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
GrainChain, Chargify, Q2, Hypergiant, NASA Tech & More TX Tech
@xconomy.com
5 years ago
Synthorx Files for IPO to Advance Enhanced Cytokine Drugs
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?